The independent laboratory Invitro will conduct research on the effectiveness of the vaccine CoviShield/AstraZeneca, a press release of the company says.
Head of the laboratory’s clinical diagnostic complex Pavlo Naboka said that the study will consist in checking the amount of antibodies that were produced after vaccination.
“According to the official instructions, the principle of action of the CoviShield vaccine is based on the development of specific immunity to the S-protein (spike) of the SARS-CoV-2 coronavirus (the causative agent of COVID-19). The presence of a sufficient amount of antibodies to this protein is a factor that protects a person from the development of the disease even in case of infection. It is possible to check how many antibodies have developed in the body after vaccination by using a new laboratory test by the world famous manufacturer Abbott Diagnostics to quantify the level of neutralizing (protective) antibo
During the entire COVID-19 vaccination process, blood samples will be taken from laboratory staff to monitor immune levels, he said. That is, the laboratory will assess how many antibodies to SARS-CoV-2 will appear in a person after the first and second vaccinations, at what rate of antibodies will be produced, whether the actual concentration of antibodies will correspond to the data reported by the vaccine manufacturer.
According to the instructions, a sufficient level of antibodies should be formed within 90 days after the first administration of the vaccine. That is, the laboratory Invitro will be able to announce the results of the study in the summer of 2021.
AstraZeneca, COVISHIELD, EFFECTIVENESS, INDEPENDENT LABORATORY, VACCINE
